Authorized purpose: Enhance GBCA-enhanced brain MRI images to improve lesion and tissue contrast for radiologist review while preserving the original post-contrast image context.
Clinical role
Background post-processing image enhancement before radiologist review.
Images and patients
MRI · Brain
Key limitation
Keep in mind: Use is tied to standard approved GBCA dosage and supported acquisition protocols. The FDA packet reports increased vessel conspicuity and false-lesion risks, including cases with major diagnostic impact, so enhanced images require radiologist review and should not be treated as an autonomous diagnostic result.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Enhance GBCA-enhanced brain MRI images to improve lesion and tissue contrast for radiologist review while preserving the original post-contrast image context.
Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Brain Input: T1 pre-contrast and standard-dose T1 post-contrast brain MRI acquired with a GBCA; listed protocols include gradient echo, 3D BRAVO, 3D MPRAGE, 2D T1 spin echo, and T1 FLAIR/inversion recovery at 0.3T, 1.5T, or 3.0T on GE, Philips, Siemens, or Hitachi systems.
Who uses it?Intended users: Radiologists in an imaging center, clinic, or hospital.
What does the software produce?Output: Enhanced DICOM MRI image with improved relative CNR, CEP, and LBR; compatible MDDS sends the result to PACS or another DICOM node for clinical review. The software has no GUI and runs in the background.
What is its most important limitation?Key limitation: Use is tied to standard approved GBCA dosage and supported acquisition protocols. The FDA packet reports increased vessel conspicuity and false-lesion risks, including cases with major diagnostic impact, so enhanced images require radiologist review and should not be treated as an autonomous diagnostic result.
Clinical takeaway. Clinical role: Enhance GBCA-enhanced brain MRI images to improve lesion and tissue contrast for radiologist review while preserving the original post-contrast image context.
Evidence takeaway. Evidence from the reviewed source record: FDA K240290 evaluated 95 T1 brain cases, including 57 with lesions, with three board-certified neuroradiologists. Quantitative improvement versus standard post-contrast images was reported for CNR, LBR, and CEP with p < 0.0001; qualitative lesion-visibility endpoints were significantly better and image quality/artifact impact was not worse, also p < 0.0001. Exploratory findings included vessel-conspicuity impact in 11.58% of AiMIFY cases versus 3.51% standard cases and major-impact false lesions in 14% of cases.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Enhance GBCA-enhanced brain MRI images to improve lesion and tissue contrast for radiologist review while preserving the original post-contrast image context.
T1 pre-contrast and standard-dose T1 post-contrast brain MRI acquired with a GBCA; listed protocols include gradient echo, 3D BRAVO, 3D MPRAGE, 2D T1 spin echo, and T1 FLAIR/inversion recovery at 0.3T, 1.5T, or 3.0T on GE, Philips, Siemens, or Hitachi systems.
Enhanced DICOM MRI image with improved relative CNR, CEP, and LBR; compatible MDDS sends the result to PACS or another DICOM node for clinical review. The software has no GUI and runs in the background.
Use is tied to standard approved GBCA dosage and supported acquisition protocols. The FDA packet reports increased vessel conspicuity and false-lesion risks, including cases with major diagnostic impact, so enhanced images require radiologist review and should not be treated as an autonomous diagnostic result.
FDA K240290 evaluated 95 T1 brain cases, including 57 with lesions, with three board-certified neuroradiologists. Quantitative improvement versus standard post-contrast images was reported for CNR, LBR, and CEP with p < 0.0001; qualitative lesion-visibility endpoints were significantly better and image quality/artifact impact was not worse, also p < 0.0001. Exploratory findings included vessel-conspicuity impact in 11.58% of AiMIFY cases versus 3.51% standard cases and major-impact false lesions in 14% of cases.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA K240290 evaluated 95 T1 brain cases, including 57 with lesions, with three board-certified neuroradiologists. Quantitative improvement versus standard post-contrast images was reported for CNR, LBR, and CEP with p < 0.0001; qualitative lesion-visibility endpoints were significantly better and image quality/artifact impact was not worse, also p < 0.0001. Exploratory findings included vessel-conspicuity impact in 11.58% of AiMIFY cases versus 3.51% standard cases and major-impact false lesions in 14% of cases.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
AiMIFY (1.x) regulatory performance study summary
DesignStand-alone performance and reader study (ACR AI Central category)
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K240290
Samplen=95
IndependenceIndependence not established
K240290
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K240290. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: T1 pre-contrast and standard-dose T1 post-contrast brain MRI acquired with a GBCA; listed protocols include gradient echo, 3D BRAVO, 3D MPRAGE, 2D T1 spin echo, and T1 FLAIR/inversion recovery at 0.3T, 1.5T, or 3.0T on GE, Philips, Siemens, or Hitachi systems.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The device receives and returns DICOM images through a compatible MDDS; the enhanced image is sent to PACS or another DICOM node. The device itself does not directly interact with the MR scanner and is described as not networked.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes AiMIFY as a software package that operates on off-the-shelf hardware (same as its predicate), running in the background without a user interface, and usable within the facility's network or remotely depending on the compatible MDDS. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Software package that operates on off-the-shelf Same Characteristics hardware" … "Because the software runs in the background, it has no user interface.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Enhanced DICOM MRI image with improved relative CNR, CEP, and LBR; compatible MDDS sends the result to PACS or another DICOM node for clinical review. The software has no GUI and runs in the background.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Enhanced DICOM MRI image with improved relative CNR, CEP, and LBR; compatible MDDS sends the result to PACS or another DICOM node for clinical review. The software has no GUI and runs in the background.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes AiMIFY as a software package that operates on off-the-shelf hardware (same as its predicate), running in the background without a user interface, and usable within the facility's network or remotely depending on the compatible MDDS. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Software package that operates on off-the-shelf Same Characteristics hardware" … "Because the software runs in the background, it has no user interface.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The device receives and returns DICOM images through a compatible MDDS; the enhanced image is sent to PACS or another DICOM node. The device itself does not directly interact with the MR scanner and is described as not networked.
Subtle Medical's current compliance page lists an annual SOC 2 Type II + HIPAA security audit, and ISO 13485:2016 (valid until 2027-07-12) and ISO/IEC 42001:2023 (valid until 2028-07-17) certificates. The page gives no audit period or report scope, and the SOC 2 report was not read.
Vendor-wide
Checked 2026-10-25
Vendor-wide statement, not an independent attestation. It does not establish certificate or report scope for this exact release, expiry, data location, retention, identity and access, or incident-response terms for a deployed configuration. Obtain these from the vendor.
ACR AI Central provides an exact-submission model card for AiMIFY (1.x); FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
21Fields reviewed
10Source classes checked
1Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate record. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K240290 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.
Authorized purpose: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.
Authorized purpose: Brain MRI morphometry and white matter hyperintensity quantification, including normative comparison and longitudinal change assessment for clinician review.
Authorized purpose: Swoop Portable MR Imaging System provides ultra-low-field point-of-care head MRI for all ages and includes deep-learning T1, T2, FLAIR, and DWI reconstruction.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.